Two new weight-loss medicines have reached US pharmacies since December 2025, both pills. One more is filed and waiting for the FDA, one is due to be filed in early 2027, and at least eleven others are in phase 3 trials. This page is the dated map of that pipeline, read on 27 October 2026 from Drugs@FDA, ClinicalTrials.gov and the companies' own statements. It looks forward only: the history of approvals is on our GLP-1 approval timeline, and the full list of drugs already on sale is on which drugs are GLP-1s. Each molecule with its own page here is linked from the table; that page carries the trial figures.
Where each one stands
| Molecule (brand) | Maker | How it acts | Status on 27 Oct 2026 | Phase 3 records* |
|---|---|---|---|---|
| Semaglutide tablet (Wegovy pill) | Novo Nordisk | GLP-1, oral | Approved 22 Dec 2025 (NDA 218316) | — |
| Orforglipron (Foundayo) | Eli Lilly | GLP-1, oral small molecule | Approved 1 Apr 2026 (NDA 220934) | 27 |
| CagriSema | Novo Nordisk | amylin + GLP-1 (two molecules) | Filed Dec 2025; no Drugs@FDA record | 22 |
| Retatrutide | Eli Lilly | GIP + GLP-1 + glucagon | Phase 3 reported; filing planned Q1 2027 | 14 |
| Amycretin (zenagamtide) | Novo Nordisk | GLP-1 + amylin in one molecule; injection and tablet | Phase 3 | 15 |
| Maridebart cafraglutide (MariTide) | Amgen | GIP-receptor-blocking antibody + GLP-1, monthly | Phase 3 | 12 |
| Survodutide | Boehringer Ingelheim | glucagon + GLP-1 | Phase 3, first results published | 12 |
| Mazdutide | Innovent (China); Lilly | glucagon + GLP-1 | Approved in China 2025; not in US | 11 |
| Eloralintide | Eli Lilly | amylin | Phase 3 | 7 |
| Ecnoglutide | Sciwind Biosciences | GLP-1 | Phase 3 (sponsor based in China) | 7 |
| VK2735 | Viking Therapeutics | GIP + GLP-1 | Phase 3 | 4 |
| Petrelintide | Zealand Pharma / Roche | amylin | Phase 3, about 7,000 people | 3 |
| Aleniglipron | Structure Therapeutics | GLP-1, oral small molecule | Phase 3 | 2 |
| Pemvidutide | Altimmune | GLP-1 + glucagon | Phase 3 | 1 |
*Our census of ClinicalTrials.gov on 27 October 2026: records tagged phase 3 whose intervention names the molecule or its code (for CagriSema, every record naming cagrilintide). Counts include completed, active and not-yet-recruiting trials and every condition studied, not only obesity. Approval data: Drugs@FDA via openFDA, same day.
Approved in the last year: the pills
The two newest approvals are both oral GLP-1 medicines, the first obesity drugs of this class that do not need an injection. The Wegovy tablet is semaglutide, the molecule in Wegovy and Ozempic, approved under its own application on 22 December 2025. Foundayo is orforglipron, a small molecule rather than a peptide, approved on 1 April 2026. Orforglipron also has the largest phase 3 programme in the table, with 27 records, because the census counts every condition Lilly is testing it in, not only obesity. How the two pills compare is on Foundayo vs the Wegovy pill. What each dose costs is on GLP-1 pills: cost.
Next in line: CagriSema and retatrutide
CagriSema is a weekly injection combining semaglutide with cagrilintide, a long-acting copy of the hormone amylin. Novo Nordisk filed it with the FDA in December 2025. On 27 October 2026 Drugs@FDA held no record for cagrilintide, so no approval had been granted, and no decision date had been published by the FDA. Its trial record, including the head-to-head it lost against tirzepatide, is on the CagriSema page.
Retatrutide acts on three receptors (GIP, GLP-1 and glucagon). Its first phase 3 obesity trial, TRIUMPH-1, was published in the New England Journal of Medicine on 29 September 2026: −25.0% at 12 mg against −3.9% on placebo over 80 weeks, counting everyone randomised (PubMed 42814954). Lilly's 23 July 2026 release says it "plans to submit a Biologics License Application (BLA) for retatrutide to FDA in Q1 2027". Its 14 phase 3 records total about 25,000 planned participants. Its safety record, dose by dose, is on retatrutide side effects, and the comparison with Zepbound is on retatrutide vs tirzepatide.
The phase 3 field, by how the drugs act
The pipeline is no longer a list of GLP-1 copies. The molecules split into four groups, and the group matters more than the brand, because it predicts both the size of the weight loss and the side-effect pattern.
- Adding glucagon — retatrutide, survodutide, mazdutide, pemvidutide. Glucagon raises energy use and acts on the liver, which is why several of these programmes include fatty-liver trials. Survodutide is compared with retatrutide on survodutide vs retatrutide.
- Adding or using amylin — CagriSema, amycretin, eloralintide, petrelintide. Amylin is released with insulin and signals fullness. The amylin-only drugs report smaller weight loss than the GLP-1 drugs, and petrelintide's phase 2 trial recorded vomiting no higher than placebo; the trade-off is set out on the petrelintide and eloralintide pages.
- Changing the GIP signal — MariTide blocks the GIP receptor while VK2735 activates it, the opposite approach, alongside GLP-1 in both. MariTide is injected monthly in its trials.
- Pills — aleniglipron and the tablet form of amycretin follow the two approved pills. Aleniglipron's phase 2b trial was published in Nature Medicine in August 2026 (PubMed 42249138); VK2735's phase 2 injection trial in Obesity in March 2026 (PubMed 41508550).
Outside these groups, bimagrumab blocks activin receptors to try to keep muscle during weight loss and is being tested with tirzepatide, and GLP-1 drugs and muscle loss explains why that question matters.
How long until the rest arrive
Every phase 3 programme in the table registers primary completion dates in 2028 or later, and the latest run to 2030–2031 (census, 27 October 2026). After a trial completes come the paper, the filing and an FDA review, which for a new obesity medicine has typically taken most of a year. So apart from CagriSema and retatrutide, none of these molecules is realistically available on prescription in the US before 2028. Those dates are not promises: trials are extended, programmes are dropped, and a filing is not an approval.
What this tracker does not do
- It does not rank the drugs. Trial figures come from different populations, lengths and ways of counting people who stopped. Each molecule's own page sets out its numbers with those details.
- It does not cover buying. Products sold online under pipeline names are not the companies' medicines. FDA has sent warning letters to sellers of "research" retatrutide, as recorded on our retatrutide page.
- It records approvals only from Drugs@FDA. A drug is listed as approved here only when the FDA's database shows it.
Whether any of these medicines, once approved, would suit a particular person is for them and their doctor to decide. This page is updated as filings and approvals happen, and each change carries its date.
Sources
Read 27 October 2026: Drugs@FDA via openFDA (NDA 218316, NDA 220934; no record for cagrilintide, retatrutide, survodutide or mazdutide); ClinicalTrials.gov API v2, phase 3 records per molecule (method above); Eli Lilly release of 23 July 2026 (retatrutide filing plan); Jastreboff et al., NEJM 2026 (PMID 42814954); Nature Medicine 2026 (PMID 42249138); Obesity 2026 (PMID 41508550); this site's molecule pages for each drug's maker, mechanism and earlier regulatory record, with their own read dates. Corrections go to the contact page.